Article PDF
Avoid common mistakes on your manuscript.
References
Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003, 299: 853–5.
Marx J. Cellular warriors at the battle of the bulge. Science 2003, 299: 846–9.
Gura T. Obesity drug pipeline not so fat. Science 2003, 299: 849–52.
Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54: 161–202.
Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 2001, 14: 65–86.
Cota D, Marsicano G, Lutz B, et al. The endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003, 27: 289–301.
Werner NA, Koch JE. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 2003, 967: 290–2.
Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410: 822–5.
Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136: 550–7.
Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002, 952: 232–8.
Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112: 423–31.
Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22: 9612–7.
Ravinet TC, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284: R345–53.
Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003, 462: 125–32.
Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144: 2195–200.
Liu J, Li H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003, 63: 983–92.
Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63: 908–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cota, D., Genghini, S., Pasquali, R. et al. Antagonizing the cannabinoid receptor Type 1: A dual way to fight obesity. J Endocrinol Invest 26, 1041–1044 (2003). https://doi.org/10.1007/BF03348205
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348205